StocksMedium•30 September 2026•
1 min read
US Court Rules Liquidia Infringed United Therapeutics Lung Disease Patents
Key Facts
1The U.S. District Court for the District of Delaware ruled that Liquidia infringes two claims of United Therapeutics' patents.
2The patents cover the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The U.S. District Court for the District of Delaware ruled that Liquidia infringes two claims of United Therapeutics' patents. Business Wire reported that the litigation centered on the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
UTHR closed at $481.47 on September 29, 2026, while LQDA closed at $70.69 on the same date. The ruling provides legal protection for United Therapeutics' intellectual property regarding its specialized lung disease treatments.